Table 1.
Effects of rapamycin on transforming activities of various oncogenes in CEF
| Oncoproteins | Rapamycin (ng/ml)
|
||
|---|---|---|---|
| 0 | 1 | 5 | |
| Group 1: inhibited | |||
| Myr-c-P3k | 100 | 0 | 0 |
| Myr-Akt | 100 | 0 | 0 |
| Group 2: unaffected | |||
| v-Src | 100 | 100 | 100 |
| v-Yes | 100 | 75 | 75 |
| v-Sea | 100 | 58 | 83 |
| v-Abl | 100 | 100 | 53 |
| v-Fps | 100 | 102 | 90 |
| v-ErbA/v-ErbB | 100 | 140 | 85 |
| v-Crk | 100 | 78 | 63 |
| v-Mos | 100 | 117 | 133 |
| v-Jun | 100 | 92 | 78 |
| v-Fos | 100 | 117 | 50 |
| Group 3: enhanced | |||
| v-Myc | 100 | 1040 | 480 |
| v-Myc/v-Mil | 100 | 1600 | 1800 |
| v-H-Ras | 100 | 1400 | 800 |
| v-Maf | 100 | 240 | Nd |
Expressed as relative efficiency of focus formation with control cultures set at 100.